The Drug Controller General of India (DCGI) has approved Takeda Biopharmaceuticals India's dengue vaccine Qdenga, making it the first dengue vaccine cleared in India. The vaccine protects against all four dengue virus strains (DENV-1 to DENV-4), can be given regardless of prior dengue exposure, and needs no pre-vaccination testing. It is administered subcutaneously as a two-dose regimen three months apart. Takeda has tied up with Hyderabad-based Biological E to make up to 50 million doses a year, so pricing is expected to be competitive. The approval is significant as India accounts for nearly one-third of the global dengue burden, with reported cases rising 11-fold over the past two decades.
Key Facts & Details
8 points- 1The DCGI approved Takeda's Qdenga — India's first dengue vaccine.
- 2It protects against all four dengue strains (DENV-1 to DENV-4) and needs no pre-vaccination testing.
- 3It is a two-dose, subcutaneous regimen given three months apart.
- 4Takeda partnered with Biological E (Hyderabad) to produce up to 50 million doses annually.
- 5India accounts for nearly one-third of the global dengue burden; cases have risen 11-fold in two decades.
Deep Dive
- +Dengue is a mosquito-borne viral disease prevalent in over 125 countries.
- +Pricing will depend partly on whether the vaccine is later added to government immunisation programmes.
- +The approval marks a major step for domestic vaccine availability against a growing public-health threat.
Exam Focus
Which company's vaccine became the first dengue vaccine approved in India by the DCGI?
Exam Relevance & Angle
A country's first vaccine against a major disease is high-yield health and science general awareness, and the regulator (DCGI), brand (Qdenga), manufacturer and dose schedule are all precise, testable facts.
Target Exams
Background & Context
Dengue is caused by four closely related virus strains, so an effective vaccine must protect against all of them at once — a long-standing scientific challenge. A key concern with dengue vaccines has been the risk of worse illness on later infection, which is why some earlier vaccines required testing for prior exposure; Qdenga is designed to be given without such pre-screening. Large-scale domestic manufacturing through a technology-transfer partnership is what makes wide, affordable roll-out feasible in a high-burden country like India.
Test Yourself
1 / 2India's first approved dengue vaccine, cleared by the DCGI, is developed by which company?
Source
This topic is important for:
